Zonisamide for Dogs – Epilepsy Treatment
Zonisamide is a sulfonamide-derived anticonvulsant for idiopathic epilepsy in dogs. Alternative to phenobarbital with fewer side effects.
Standard Dose
| Indication | Dose | Frequency |
|---|---|---|
| Monotherapy | 5-10 mg/kg | Every 12 hours |
| With phenobarbital | 10-15 mg/kg | Every 12 hours |
| Refractory | 10-15 mg/kg | Every 12 hours |
Start at lower end and titrate.
Dose Reference Table (5 mg/kg q12h)
| Weight | Dose | Capsules |
|---|---|---|
| 5 kg | 25 mg | 1 × 25 mg |
| 10 kg | 50 mg | 1 × 50 mg |
| 15 kg | 75 mg | 1.5 × 50 mg |
| 20 kg | 100 mg | 1 × 100 mg |
| 30 kg | 150 mg | 1.5 × 100 mg |
| 40 kg | 200 mg | 2 × 100 mg |
Pharmacokinetics
- Steady state: 5-7 days
- Half-life: ~15 hours in dogs
- Target serum trough: 10-40 mcg/mL
- Trough timing: Just BEFORE next dose
- Hepatic metabolism + renal elimination
Monitoring Schedule
- Baseline bloodwork before starting
- Seizure diary – frequency, duration, severity
- Serum trough at 2-3 weeks (steady state)
- Recheck every 6 months
- After dose change – 2-3 week recheck
- Annual bloodwork
Anticonvulsant Comparison
| AED | Dose | Notes |
|---|---|---|
| Phenobarbital | 2-5 mg/kg q12h | First-line; hepatotoxicity risk; trough 25-35 mcg/mL |
| Zonisamide | 5-10 mg/kg q12h | Fewer side effects; sulfa concerns; trough 10-40 |
| Levetiracetam (Keppra) | 20-30 mg/kg q8h | Best side effect profile; expensive |
| Potassium bromide | 20-40 mg/kg/day | Adjunct; long half-life |
| Felbamate | 15-65 mg/kg q8h | Refractory; bloodwork monitoring |
âš Phenobarbital Co-Administration
- Phenobarbital INDUCES hepatic CYP enzymes
- Increases zonisamide metabolism
- Need HIGHER zonisamide dose (10-15 mg/kg)
- When discontinuing phenobarbital – reduce zonisamide
- Common combination for refractory epilepsy
Side Effects
Common
- Mild sedation (improves 2-4 weeks)
- Mild ataxia
- Decreased appetite (transient)
Uncommon
- Hepatotoxicity (rare)
- Renal tubular acidosis (rare)
- Urinary crystals/stones (sulfonamide)
- Behavioral changes
Rare
- Severe hepatotoxicity
- Aplastic anemia
- Severe skin reactions
âš Contraindications
- SULFONAMIDE HYPERSENSITIVITY – avoid in sulfa-allergic dogs
- Severe hepatic dysfunction
- Severe renal dysfunction
- Pregnancy – teratogenic potential
- Lactation
Drug Interactions
- Phenobarbital – induces metabolism (higher dose needed)
- CYP3A inhibitors (ketoconazole, cimetidine) – increase levels
- Other AEDs – additive sedation
- Acetazolamide – additive metabolic acidosis
âš Never Abruptly Discontinue
- Withdrawal seizures can occur
- Taper over 4-8 weeks minimum
- Cross-titrate when switching to another AED
- Some dogs need lifelong therapy
Frequently Asked Questions
How much zonisamide should I give my dog?
STANDARD DOSE: 1) MONOTHERAPY – 5-10 mg/kg PO every 12 hours (start 5 mg/kg, titrate); 2) WITH PHENOBARBITAL – 10-15 mg/kg q12h (phenobarbital induces metabolism); 3) REFRACTORY – 10-15 mg/kg q12h. EXAMPLES (5 mg/kg q12h): 5 kg = 25 mg; 10 kg = 50 mg; 15 kg = 75 mg; 20 kg = 100 mg; 30 kg = 150 mg; 40 kg = 200 mg. FORMULATIONS: 1) 25, 50, 100 mg capsules; 2) Compounded for precise small dog dosing; 3) Cannot be split (powder inside). ADMINISTRATION: 1) With or without food; 2) Same time daily; 3) Every 12 hours; 4) Don’t miss doses; 5) Make up missed dose if soon, otherwise skip and resume next dose – NEVER double-dose. STEADY STATE achieved in 5-7 days. TARGET SERUM TROUGH 10-40 mcg/mL drawn JUST BEFORE next dose. Adjust based on seizure control + serum levels + side effects. Lifelong therapy typical for idiopathic epilepsy.
Zonisamide vs phenobarbital – which is better?
DEPENDS on individual dog. Both effective, different profiles. PHENOBARBITAL ADVANTAGES: 1) FIRST-LINE traditionally; 2) Inexpensive (generic widely available); 3) Effective in 60-80% of dogs; 4) Long track record + extensive data; 5) Once-twice daily dosing; 6) Excellent serum level monitoring established. PHENOBARBITAL DISADVANTAGES: 1) HEPATOTOXICITY risk – significant; 2) Sedation/ataxia (usually transient); 3) Polyuria/polydipsia/polyphagia; 4) Weight gain; 5) Cognitive effects long-term; 6) Bloodwork monitoring (CBC, chemistry, bile acids) essential; 7) Behavioral changes; 8) Possible idiosyncratic reactions (rare bone marrow). ZONISAMIDE ADVANTAGES: 1) FEWER SIDE EFFECTS overall; 2) No significant hepatotoxicity; 3) Mild sedation only (improves); 4) Once-twice daily; 5) Effective monotherapy; 6) Adjunct potential; 7) Better cognitive profile; 8) No polyuria/polyphagia. ZONISAMIDE DISADVANTAGES: 1) More expensive; 2) SULFONAMIDE – cannot use in sulfa-allergic dogs; 3) Rare renal tubular acidosis; 4) Possible urinary crystals; 5) Less data than phenobarbital; 6) Newer AED. WHEN PHENOBARBITAL PREFERRED: 1) Cost-sensitive owner; 2) First-line treatment for uncomplicated epilepsy; 3) Severe seizures requiring rapid loading; 4) Established protocol familiar; 5) No sulfa allergy concern; 6) No hepatic disease. WHEN ZONISAMIDE PREFERRED: 1) HEPATIC concerns (existing liver disease or worry about phenobarbital toxicity); 2) Phenobarbital not tolerated (sedation, behavior changes); 3) Owner reluctance to use phenobarbital; 4) ADD-ON to phenobarbital for refractory cases; 5) Sensitive to cognitive effects; 6) No sulfa allergy. COMMON SCENARIOS: 1) NEW EPILEPSY DIAGNOSIS – either acceptable; many vets choose phenobarbital first due to data + cost; some choose zonisamide for side effect profile; 2) PHENOBARBITAL INADEQUATE – add zonisamide; 3) PHENOBARBITAL HEPATIC concerns – switch to zonisamide; 4) PHENOBARBITAL POORLY TOLERATED – switch to zonisamide or Keppra; 5) REFRACTORY – combination therapy. SWITCHING phenobarbital to zonisamide: 1) Add zonisamide first; 2) Reach therapeutic level; 3) Gradually taper phenobarbital over weeks; 4) Monitor serum levels; 5) Adjust zonisamide dose as phenobarbital decreases; 6) Goal: lowest effective doses. LEVETIRACETAM (KEPPRA) – another excellent option: 1) Best side effect profile; 2) Expensive; 3) Three-times daily standard (ER form twice-daily); 4) Renal elimination; 5) Often added third-line. PROGNOSIS: 1) 60-80% of dogs respond to first AED; 2) 20-30% need polytherapy; 3) Goal: seizure-free or significant reduction; 4) Lifelong management; 5) Quality of life primary; 6) Individualize approach. WORK WITH VETERINARY NEUROLOGIST for complex cases. DACVIM (Neurology) consultation valuable for refractory epilepsy.
How long does zonisamide take to work in dogs?
STEADY STATE in 5-7 DAYS. Full clinical effect assessed at 2-3 WEEKS. TIMELINE: 1) DAY 1-2: drug entering system; partial effects possible; 2) DAY 5-7: STEADY STATE achieved; therapeutic levels established; 3) WEEK 1-2: clinical response developing; sedation prominent initially; 4) WEEK 2-3: maximum effect; check serum trough; assess seizure frequency; 5) MONTH 1-3: long-term effect established; adjust dose if needed; 6) ONGOING: lifelong therapy; periodic monitoring. WHEN TO ASSESS RESPONSE: 1) 2-3 weeks after starting (steady state + clinical effect); 2) 2-3 weeks after dose change; 3) Compare seizure frequency vs baseline; 4) Document with seizure diary; 5) Account for individual variation; 6) Consider serum levels. SERUM MONITORING SCHEDULE: 1) Baseline before starting; 2) 2-3 WEEKS after starting (trough just before next dose); 3) Every 6 MONTHS once stable; 4) After dose changes – 2-3 weeks; 5) After adding/removing other AEDs; 6) If breakthrough seizures; 7) Target trough 10-40 mcg/mL. WHAT TO EXPECT: 1) SEIZURE FREQUENCY reduction – goal 50%+ reduction first 3 months; 2) SEIZURE-FREE – possible but not always achieved; 3) GRADUAL improvement; 4) Some dogs need multiple medication combinations; 5) Realistic expectations – control not cure typically. SIDE EFFECTS TIMELINE: 1) DAY 1-2: sedation prominent; 2) WEEK 1-2: ataxia + sedation; usually improving; 3) WEEK 2-4: side effects diminishing; 4) MONTH 1+: well-tolerated typically. IF NOT WORKING after 3-4 weeks: 1) Verify dose adequate; 2) CHECK SERUM LEVELS (target 10-40 mcg/mL); 3) Increase dose if below target; 4) Add second AED if at upper dose; 5) Reassess diagnosis – is it truly epilepsy?; 6) MRI/CSF if not done (structural causes); 7) Veterinary neurologist consultation. PATIENCE REQUIRED: 1) Don’t judge too early; 2) Individual response varies; 3) Combination therapy common; 4) Adjust dose based on response; 5) Long-term commitment; 6) Owner education essential. SEIZURE DIARY essential: 1) DATE + TIME each seizure; 2) DURATION; 3) PRE-ICTAL (before) signs; 4) ICTAL signs (during seizure); 5) POST-ICTAL signs (after); 6) Trigger if identifiable; 7) Medication compliance; 8) Cluster seizures noted; 9) Photo/video if safe; 10) Share with vet at visits. ADJUSTMENT STRATEGIES: 1) Inadequate response – increase dose; 2) Side effects – decrease dose; 3) Breakthrough seizures despite therapeutic levels – add second AED; 4) Cluster seizures – rescue medication (rectal diazepam, midazolam); 5) Status epilepticus – emergency. WORK WITH VETERINARIAN OR NEUROLOGIST for optimal management. Don’t make changes without consultation. Don’t abruptly discontinue.
Can my dog stop taking zonisamide after being seizure-free?
MAYBE – but ALWAYS taper gradually under veterinary supervision. NEVER abruptly stop. CONSIDERATIONS for discontinuation: 1) 1-2 YEARS seizure-free typically minimum; 2) Some experts recommend 2-3 years; 3) Underlying cause (idiopathic vs structural); 4) Drug levels were therapeutic; 5) Quality of life on medication; 6) Owner comfortable with risk; 7) Owner can monitor + restart if needed; 8) Lifestyle considerations. RISK FACTORS for SEIZURE RECURRENCE on discontinuation: 1) History of cluster seizures or status epilepticus; 2) Multiple AEDs needed for control; 3) Difficulty achieving control initially; 4) Structural brain lesions; 5) Family history; 6) Young age at onset; 7) High seizure frequency at diagnosis; 8) Need for therapeutic serum levels above mid-range. TAPER PROTOCOL: 1) NEVER abruptly discontinue – WITHDRAWAL SEIZURES possible; 2) TAPER OVER 4-8 WEEKS MINIMUM; 3) Reduce dose 25% every 1-2 weeks; 4) MONITOR closely during taper; 5) If seizures occur – return to previous dose; 6) Re-evaluate decision; 7) Some dogs need lifelong therapy; 8) Document everything; 9) Maintain communication with vet. EXAMPLE TAPER (40 mg BID): 1) Week 1-2: 40 mg BID (baseline); 2) Week 3-4: 30 mg BID (25% reduction); 3) Week 5-6: 20 mg BID; 4) Week 7-8: 10 mg BID; 5) Week 9+: discontinue if stable; 6) Some dogs need longer taper. IF ON MULTIPLE AEDs: 1) Discontinue one at a time; 2) Wait several months between changes; 3) Monitor levels of remaining medications; 4) Most dogs need at least one AED long-term; 5) Specialist consultation valuable. MONITORING DURING TAPER: 1) Daily observation; 2) Seizure diary; 3) Owner availability for monitoring; 4) Rescue medication available (rectal diazepam); 5) Emergency vet contact info; 6) Document any concerning signs. IF SEIZURE OCCURS during taper: 1) IMMEDIATELY return to previous effective dose; 2) Continue at that dose; 3) Reassess discontinuation plan; 4) May need lifelong therapy; 5) Consider alternative AED; 6) Veterinary consultation. POST-DISCONTINUATION monitoring: 1) Continue seizure diary; 2) Observe for 6-12 months; 3) Recurrence may occur months later; 4) Stress, illness, hormones can trigger; 5) Maintain emergency plan; 6) Have rescue meds available; 7) Periodic vet visits. WHEN DISCONTINUATION NOT RECOMMENDED: 1) Significant ongoing risk factors; 2) Previous failed taper attempts; 3) Owner unable to monitor; 4) No emergency vet access; 5) Multiple AEDs needed for control; 6) Structural brain lesion; 7) High-risk lifestyle (working dog); 8) Owner preference for stability. REALISTIC EXPECTATIONS: 1) Some dogs successfully discontinue; 2) Many need lifelong therapy; 3) Quality of life on medication usually good; 4) Side effects manageable typically; 5) Better safe than sorry approach; 6) Veterinary guidance essential. NEUROLOGIST CONSULTATION: 1) Specialist input valuable; 2) Personalized risk assessment; 3) Long-term planning; 4) Advanced testing if needed (MRI, CSF); 5) Optimized treatment protocols; 6) Quality of life optimization. DON’T MAKE CHANGES WITHOUT VETERINARY GUIDANCE. Sudden discontinuation can cause life-threatening status epilepticus.
Related PuppaDogs Calculators
Continue building your dog’s personalised care plan with these related PuppaDogs calculators:
- Dog Pregnancy / Whelping Due-Date Calculator
- Puppy Weight Predictor (Adult Weight Calculator)
- Heatstroke Risk Calculator for Dogs
- Bloat (GDV) Risk Calculator for Dogs
- Dog Life Expectancy Calculator (Breed, Body Condition, Lifestyle)
- Spay/Neuter Timing Calculator for Dogs (Breed-Specific)
Related Articles & Guides
Read the in-depth PuppaDogs guides that explain the science and clinical context behind this calculator:
References & Further Reading
The dosing ranges and safety information on this page are drawn from the following veterinary references. Always defer to your own veterinarian and the manufacturer’s label for your specific product.
- Plumb DC. Plumb’s Veterinary Drug Handbook – zonisamide.
- Dewey CW et al. Zonisamide therapy for refractory idiopathic epilepsy in dogs.
- Boothe DM et al. Comparison of phenobarbital versus zonisamide.
- ACVIM Consensus on the Diagnosis and Management of Canine Idiopathic Epilepsy.
- Podell M. Antiepileptic drug therapy.
- Dewey CW. Canine and Feline Neurology.
- PuppaDogs. Idiopathic Epilepsy Calculator, Levetiracetam Calculator. puppadogs.com.
















